Rigel Pharma (RIGL) Reports In-Line Q4 EPS
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $35.61 --0%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $8.9 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Darden Restaurants (DRI) PT Raised to $235 at Guggenheim
- Crown Crafts (CRWS) Reports Q4 EPS of $0.03
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
